Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Kits d'Essai > Kits d'Essai ADA
Favezelimab ELISA Kit
Favezelimab ELISA Kit
Prix(USD) :
Spécification :
  • 96T
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueDB613038
Description
Favezelimab ELISA Kit (DB613038) — Quantitative sandwich ELISA for Favezelimab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
  • ●Sandwich Format — High specificity, reliable quantification.
  • ●High Sensitivity — Optimized for low-abundance target detection.
  • ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillonPlasma, Serum
Sensibilité0.156 μg/ml
Plage0.31-5 μg/mL
Numéro d'accès P18627
Applications ELISA
Méthode de détection Colorimetric
Type de test Quantitative
Retraitement 80-120%
Expédition 2-8 ℃
Stabilité et stockage The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications

Favezelimab

Noms alternatifsMK-4280, Mavezelimab (PL123)
Contexte

Lymphocyte activation gene 3 protein (Favezelimab) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1.

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648
2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082
3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750
4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185
5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966
6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841
7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469
8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152
10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
Note For Research Use Only.
Images
  • Favezelimab ELISA Kit

    Standard Curve

    Standard Curve of Favezelimab ELISA Kit

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs